04 February 2019 by Angel Cogolludo

Activation of Kv7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation

The nitric oxide-NO/cGMP pathway represents a major physiological signalling controlling pulmonary arterial (PA) tone and drugs activating this pathway are used to treat pulmonary arterial hypertension.

Kv channels expressed in PA smooth muscle cells (PASMC) are key determinants of vascular tone. We aimed to analyse the contribution of Kv1.5 and Kv7 channels in the electrophysiological and vasodilating effects evoked by NO donors and the guanylate cyclase (GC) stimulator riociguat in PA. Kv currents were recorded in isolated rat PASMC using the patch-clamp technique. Vascular reactivity was assessed in a wire myograph. The NO donors DEA-NO and SNP hyperpolarized the membrane potential and induced a bimodal effect on Kv currents (augmenting the current between -40 to -10 mV and decreasing it at more depolarized potentials). The hyperpolarization and the enhancement of the current were suppressed by Kv7 channel inhibitors and by the GC inhibitor ODQ but preserved when Kv1.5 channels were inhibited. Additionally, DEA-NO enhanced Kv7.5 currents in COS7 cells expressing KCNQ5 gene. Riociguat increased Kv currents at all potentials ≥-40 mV and induced membrane hyperpolarization. Both effects were prevented by Kv7 inhibition. Likewise, PA relaxation induced by NO donors and riociguat was attenuated by Kv7 inhibitors. In conclusion NO donors and riociguat enhance Kv7 currents, leading to PASMC hyperpolarisation. This mechanism contributes to NO/cGMP-induced PA vasodilation. Our study identifies Kv7 channels as a novel mechanism of action of vasodilator drugs used in the treatment of pulmonary arterial hypertension. 

 

Supported by the Spanish Ministry of Economy and Competitiveness (SAF2016-77222-R), the Cardiovascular Medical Research and Education Fund and Fundación Contra la Hipertensión Pulmonar-EMPATHY.

About the author


profile picture of Angel Cogolludo

Angel Cogolludo

Departamento Farmacología,Facultad de Medicina, Universidad Complutense de Madrid

Spain

Key Contributors

Angel Cogolludo 1,2, Gema Mondéjar-Parreño 1,2, Javier Moral-Sanz 1,2, Bianca Barreira 1,2, Alicia De la Cruz 4,5, Maria Callejo 1,2, Sergio Esquivel-Ruiz 1,2, Daniel Morales-Cano 1,2, Laura Moreno 1,2, Carmen Valenzuela 4,5, Francisco Perez-Vizcaino : 1.Department of Pharmacology and Toxicology, School of Medicine, University Complutense of Madrid, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, 2.Ciber Enfermedades Respiratorias (CIBERES), Spain. 4.Instituto de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM Spain. 5.CIBER Enfermedades Cardiovasculares (CIBERCV), Spain.


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg